Partner Headlines - AMGN

  1. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus
  2. Insider Buys at Halozyme Look to Improve Stock Outlook

    GuruFocus
  3. Amgen, Inc. Poised To Break Higher

    Benzinga
  4. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab ...

    Benzinga
  5. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare ...

    Benzinga
  6. Amgen, Inc. Showing More Upside Potential

    Benzinga
  7. Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding

    Benzinga
  8. Novartis, Regeneron Cardio Results Pump Up Wall St.

    IBD
  9. Novartis, Regeneron Hit New Highs On Cardio Drugs

    IBD
  10. Amgen edges up on trial results

    IBD
  11. Stocks Hitting 52-Week Highs

    Benzinga
  12. Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

    Benzinga
  13. After Reaching All-Time Highs, How Can Gilead Sciences Continue ...

    GuruFocus
  14. HCP Boosts Of 29 Years Of Dividend Increases

    IBD
  15. The Tech Industry is Vanishing Before Our Eyes

    FoxBusiness
  16. Stocks End With Small Gains; Amgen Shrugs Off Drug Data

    IBD
  17. AMGEN

    IBD
  18. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  19. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  20. Cancer 'Cocktail' Passes Test

    IBD
  21. Nasdaq Leads In Quiet Session; Priceline Nears Buy Point

    IBD
  22. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD
  23. Morning Market Movers

    Benzinga
  24. Benzinga's Top #PreMarket Gainers

    Benzinga
  25. UPDATE: Amgen Announces Phase 3 ASPIRE Trial of Kyprolis Met ...

    Benzinga
  26. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga
  27. Amgen Price Target Raised by Various Analysts

    Benzinga
  28. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  29. Quarterly “Beats”: Bah, Here Are Real Growers

    YCharts
  30. Amgen To Slash Workforce

    IBD
  31. Indexes End Lower As Russia Sanctions Hit Stocks

    IBD
  32. Stock Futures Show Some Muscle; Merck, Cognex Rising

    IBD
  33. Earnings Scheduled For July 29, 2014

    Benzinga
  34. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  35. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  36. Benzinga Weekly Preview: FOMC In Focus, As Earnings Season Progresses

    Benzinga
  37. US Stock Futures Drop Ahead Of Durable Goods Orders Data

    Benzinga
  38. Biotech Enters Reporting Season With Large Caps Central To Sector ...

    Benzinga
  39. UPDATE: Amgen Announces Positive Phase 3 Results For AMG 416 ...

    Benzinga
  40. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  41. Morgan Stanley Issues 2015 'Vintage Values' Stock List

    Benzinga
  42. Celgene Drug Otezla Fails Trial, But Street Sanguine

    IBD
  43. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  44. Bind Therapeutics

    IBD
  45. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  46. Bind Therapeutics Down After Losing Amgen Partnership

    IBD
  47. Dow Hits 17,000 On Jobs Report; Walgreen Same-Store-Sales Surge ...

    Benzinga
  48. Morning Market Losers

    Benzinga
  49. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga
  50. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  51. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  52. UPDATE: Morgan Stanley Reiterates On Amgen On New CFO

    Benzinga
  53. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  54. UPDATE: Morgan Stanley Reiterates On Amgen Following AMAGINE-1 ...

    Benzinga
  55. Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and ...

    GuruFocus
  56. Amgen

    IBD
  57. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ...

    Benzinga
  58. Amgen Blazed Biotech Trail, Earned 165,233% Reward

    IBD
  59. Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple ...

    Benzinga
  60. Stocks End Six-Day Win Streak As Techs Sell Off

    IBD
  61. Stock Futures Mixed And Busy; Illumina Rockets, Cree Tumbles

    IBD
  62. #PreMarket Primer: Wednesday, April 23: Data From China Takes ...

    Benzinga
  63. AMGEN

    IBD
  64. Gilead Soars As Hep C Drug Shatters Views; Amgen Misses

    IBD
  65. Rallying Ahead of Earnings

    FoxBusiness
  66. Nasdaq, S&P 500 On Track For Sixth Straight Gain

    IBD
  67. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  68. Stocks Power Out Early Gains; Allergan Leads Drug-Maker Surge

    IBD
  69. Earnings Scheduled For April 22, 2014

    Benzinga
  70. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  71. Short Interest Rises As Biotechs Fall (AMGN, CELG, DNDN)

    Benzinga
  72. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  73. UPDATE: Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable ...

    Benzinga
  74. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  75. Cholesterol drug meets goal

    IBD
  76. Trial Results Lift Drug Sector

    IBD
  77. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  78. Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

    Benzinga
  79. Gilead Adds To Biotech Woes

    IBD
  80. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  81. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  82. Market Wrap For March 27: Markets Lower Following Mixed Economic ...

    Benzinga
  83. Biotech ETFs Come Back Down To Earth

    Benzinga
  84. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  85. BIOGEN IDEC

    IBD
  86. Have We Seen The Top Of The Market?

    Benzinga
  87. Market Wrap For March 18: Markets Positive Despite Crimea Concerns

    Benzinga
  88. Amgen up on drug trial result

    IBD
  89. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  90. US Stock Futures Edge Lower Ahead Of Wholesale Trade Data

    Benzinga
  91. Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results ...

    Benzinga
  92. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  93. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  94. Insys Set To Report Q4 Earnings With Stock Surging

    IBD
  95. Why Stock Shakeouts Can Be Scary, Yet Constructive

    IBD
  96. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  97. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  98. Revenue Growth: Focus On Healthcare Stocks

    YCharts
  99. France's Biosimilar Substitution May Lead to Erosion of Amgen

    Benzinga
  100. Why Mr. Cautious Is 82% Invested In Stocks

    YCharts
Trading Center